Status:
COMPLETED
Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet
Lead Sponsor:
Eli Lilly and Company
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to estimate drug preference of stable schizophrenic patients who will be treated with olanzapine orodispersible tablets for 6 weeks then with olanzapine tablets for 6 weeks...
Eligibility Criteria
Inclusion
- You are an outpatient diagnosed with stable schizophrenia.
- You are a male or female in the age of 18 to 65 years old.
- You are retrospectively judged by investigators, based on clinical interview and impression, to have been stable for at least 4 weeks.
- You must be able to take olanzapine orodispersible in a single daily dose.
- You are treated with conventional oral olanzapine tablet (as monotherapy) for at least 1 month.
Exclusion
- You have used olanzapine in the past and are no longer using it because of a bad reaction.
- You have known Human immunodeficiency virus positive (HIV+) status.
- You have known uncorrected, narrow angle glaucoma.
- You have known Leukopenia, (abnormally low white blood cell count).
- You have a serious or uncontrolled illness (for example: liver disease, history of heart disease, or inadequately controlled diabetes.)
- You have Parkinson's disease.
- You are a female patient who is either pregnant or nursing
- You are taking medications that are not allowed in the study.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
284 Patients enrolled
Trial Details
Trial ID
NCT00324051
Start Date
May 1 2006
End Date
September 1 2007
Last Update
September 12 2019
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Rio de Janeiro, Brazil, 21020-130
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Constanța, Romania
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Adana, Turkey (Türkiye)
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ankara, Turkey (Türkiye)